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Small Vessel Replacement
by Human Umbilical Arteries With
Polyelectrolyte Film-Treated Arteries
In Vivo Behavior
Halima Kerdjoudj, PHD,* Nicolas Berthelemy, PHD,* Simon Rinckenbach, MD, PHD,§
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Patrick Lacolley, MD, PHD,‡ Jean-François Stoltz, PHD,* Jean-Claude Voegel, PHD,#
Patrick Menu, PHD*
Vandoeuvre-lès-Nancy and Strasbourg, France
Objective The aim of this study was to evaluate the patency of human umbilical arteries treated with polyelectrolyte multi-
layers (PEMs) after rabbit implantation.
Background The development of small-caliber vascular substitutes with high patency after implantation remains a real chal-
lenge for vascular tissue engineering.
Methods Cryopreserved human umbilical arteries were enzymatically de-endothelialized and the luminal surfaces were coated
with poly(styrene sulfonate)/poly(allylamine hydrochloride) (PSS/PAH) multilayers. The PEM-untreated arteries and
PEM-treated rabbit carotids were used as graft control. The native rabbit carotids were bypassed by grafts.
Results The Doppler ultrasound evaluation, performed in vivo, showed that all PEM-treated grafts remained patent dur-
ing the full experimental period, whereas after only 1 week, no blood circulation was detected in untreated arter-
ies. Scanning electron microscopy and histological graft examination showed pervasive thrombus formation on
the luminal surface of untreated arteries after 1 week and clean luminal surface for treated arteries for at least
up to 12 weeks. The arterial wall cells were identified through alpha-smooth muscle actin  platelet endothe-
lial cell adhesion molecule-1 expression. The smooth muscle cells positive to alpha-smooth muscle actin were
identified in adventitia and media and the endothelial cells positive to platelet endothelial cell adhesion mole-
cule in intima. Von Kossa reaction didn’t reveal any calcium salt deposits on the wall arteries, suggesting a good
wall remodelling with no sign of graft rejection.
Conclusions The in vivo evaluation of human umbilical arteries treated with PSS/PAH multilayers demonstrated a high graft pa-
tency after 3 months of implantation. Such modified arteries could constitute a useful option for small vascular
replacement. (J Am Coll Cardiol 2008;52:1589–97) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.08.009s
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bascular diseases, with their high rates of morbidity and
ortality in patients, are one of the most challenging
esearch domains in medical science. Vascular grafts are of
From the Group of Bioengineering (LEMTA-UMR CNRS 7563), †INSERM Unité
84, Centre d’Investigation Clinique de Nancy (CIC-P 9501), and ‡INSERM Unité
84, School of Medicine, Nancy University, Vandoeuvre-lès-Nancy, France; §ERT 1061,
LP Strasbourg, France; Department of Pathology, Hôpital de Brabois Adultes,
andoeuvre-lès-Nancy, France; ¶Charles Sadron Institut (UPR 22, CNRS), Strasbourg
edex, France and #INSERM Unité 595, Odontology Faculty, Louis Pasteur University,
trasbourg, France. This work was partly supported by Région de Lorraine (PRST
ioengineering) and Agence Nationale pour la Recherche (Projet: SUBVACEL
NR-07-TECSAN-022-01). Drs. Kerdjoudj and Berthelemy contributed equally to
his work.t
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ccepted August 4, 2008.ynthetic or biological origin. Synthetic grafts are most
ommonly made of Dacron (Invista, Inc., Charlotte, North
arolina) or polytetrafluroethylene; however, their high
hrombogenic surface and poor mechanical properties limit
heir use as small-caliber grafts. For this reason, the use of
utologous vessels (saphenous veins) constitutes an alterna-
ive choice for patients in need of small-caliber arterial
econstruction. The use of autografts is nevertheless ham-
ered by limited availability and suitability as the result of
xtensive peripheral vascular diseases and/or their previous
ses in bypass surgery.
An alternative vessel source could originate from allograft
anks (1–3). Arterial allografts usually are used for in situ
reatment of infected prosthetic grafts (4,5). A major
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PEM-Treated Artery: A Patent Vascular Graft November 4, 2008:1589–97advantage related to allografts is
their greater abundance compared
with autografts and their adequate
vascular architecture for small ves-
sel replacements. Nevertheless,
cryopreserved arteries exhibit sev-
eral limits such as an increased risk
of thrombogenicity due to endo-
thelium loss (6–8) and an in-
creased risk of intimal hyperplasia
formation due to a decrease of
mechanical properties (9,10).
Thus, innovative technologies
aimed to modify small-diameter
natural grafts to obtain functional
blood vessels with antithrombo-
genic and adequate mechanical
properties comparable with native
vessels constitute challenging re-
search domains and are of the
highest clinical importance. At-
tempts have been made to reduce
the inherent thrombogenicity of
vascular graft surfaces by autolo-
gous fibrin coating (11–13) or by
integrating some of the processes
specific to vascular endothelium
function such as heparin (14–16).
owever, the strongest drawback of the use of heparin remains
he risk of heparin-induced thrombocytopenia (17,18). More-
ver, their short lifespan and the transient coating lead often to
raft failures and after its crosslinking onto luminal surface of
atural vessels it decreases arterial compliance (19,20).
The layer-by-layer self assembly of polyanions and poly-
ations and the resulting polyelectrolyte multilayer films
PEMs) constitute excellent candidates for tissue engineer-
ng applications because of their biocompatibility and bioin-
rtness. This approach also was used for blood vessel coating
21). Elbert et al. (22) found that the use of polylysine/
lginate PEM prevents cell attachment. More recently,
hierry et al. (21) deposited hyaluronan/chitosan films
irectly on damaged arteries. Moreover, this “in vitro”
xperiment exhibited very weak platelet and leukocyte
dhesion on films ended by a polyanion layer, thus avoiding
he thrombogenic process.
We also demonstrated recently the possibility of depos-
ting a poly(allylamine hydrochloride)/poly(styrene sulfo-
ate) (PAH/PSS) multilayer directly inside arteries that
riginated from umbilical cords (UCs) (23). We showed
hat, after the deposition of such a film built with only 3.5
airs of layers, the initial compliance of the tissue was
ecovered. Such a recovery is of main importance in partic-
lar to avoid an intimal hyperplasia at the anastomotic site
24,25).
The aim of the present work, then, was to use this
Abbreviations
and Acronyms
CLSM  confocal laser
scanning microscopy
H&S  hematoxylin and
eosin/safran
HUA  human umbilical
artery
PAH  poly(allylamine
hydrochloride)
PECAM  platelet
endothelial cell adhesion
molecule
PEM  polyelectrolyte
multilayer film
PSS  poly(styrene
sulfonate)
RPMI/BSA  RPMI1640
containing 0.5% bovine
serum albumin
SEM  scanning electron
microscopy
SMA  smooth muscle
actin
SMC  smooth muscle cell
UC  umbilical cord
UnA  untreated arterytrategy to coat the lumen of UC arteries by (PAH/PSS)3 llms with the objective of conferring them patency prop-
rties (antithrombogenic properties and good mechanical
ehavior). We chose the PAH/PSS system because it is
nown to be one of the most stable PEM systems and
hould be resistant to enzymatic degradations, and also
ecause the deposition of 3.5 pairs of layers restored the
nitial compliance of umbilical arteries (26). We directly
hecked the validity of the concept in an animal model and
ypassed native carotids with PEM-treated cryopreserved
enografts (human umbilical artery [HUA]). The main
eason for the choice of HUA as vascular blood substitutes
n these experimental models was that xenogenic materials
llowed us to test a source of abundant products for human use.
ethods
olyelectrolyte and graft arteries preparation. We pur-
hased PSS and PAH (molecular weight  70 kDa) from
igma (St. Louis, Missouri) and used them without further
urification. The PEMs were built from PSS and PAH
olutions at 5 mg/ml dissolved in 10 mmol/l Tris and 150
mol/l/ NaCl buffer, pH 7.4. The arteries were carefully
arvested from UCs and cryopreserved as previously de-
cribed (23). After 3 months of storage, the cryopreserved
rteries were thawed in 37°C water and de-endothelialized
y an enzymatic digestion with trypsin/ethylene diamine
etraacetic acid. Rabbit-cryopreserved carotids, used as con-
rol, were subjected to the same protocol.
eposition of PEM into de-endothelialized allo and
enogenic arteries. The PAH solution was incubated in-
ide the de-endothelialized arteries for 15 min. The arteries
ere extensively rinsed with Tris/NaCl buffer. In accor-
ance with this previous procedure, the PSS and PAH were
dsorbed alternatively for 15 min, with 2 consecutive ad-
orption steps being separated by 3 rinsing steps of 15 min
ith buffer. Thus, a (PAH-PSS)3 film was progressively
uilt. Untreated arteries (UnAs) also were subjected to
everal rinses with buffer and used as control. After PEM
uild-up, arteries were stored 12 h at 4°C in RPMI1640
edium (Sigma) supplemented with 100 UI/ml penicillin,
00 g/ml streptomycin, and 2.5 g/ml Fungizone (Gibco
RL, Grand Island, New York).
abbit carotid bypass surgery. Animal care complied with
he Principle of Laboratory Animal Care and the Guide for
he Care and Use of Laboratory Animals (National Institute
f Health publication no. 80-23, revised 1978). A total of 18
ew Zealand White rabbits (male, average weight 3 to 3.5
g, CEGAV, Saint-Mars-d’Egrenne, France) were used for
ommon carotid bypass surgery. Anaesthesia was induced
y intravenous injection of sodium pentobarbital (40 mg/kg,
eva Santé Animale, Libourne, France). After systemic
eparinization (300 IU/kg, Sanofi Synthelabo, Paris,
rance), the common carotid artery was isolated and divided
etween vascular clamps to stop blood flow. A proximal
ongitudinal arteriotomy was made, and one end of grafts
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November 4, 2008:1589–97 PEM-Treated Artery: A Patent Vascular Graftuntreated [n 6] and arteries treated with PEM [n 12])
ere anastomosed to the artery end-to-side, with continu-
us sutures. The distal anastomosis was performed similarly,
nd the native carotids were bound to shunt the blood flow
hrough the implanted grafts. Neither anticoagulant nor
ntiplatelet agents were administered, except for the intra-
perative heparin. After 1, 4, 7, and 12 weeks of implanta-
ion, the animals were anesthetized, grafts were removed,
nd the animals were sacrificed by anaesthetic lethal dose.
oppler ultrasound examination. Post-operatively, the
raft patency was evaluated, regularly up to 12 weeks, by
anual palpation of the pulse and direct observation of
lood flow with echo-Doppler technique (Sonos 7500
ystem, Philips Healthcare, Best, the Netherlands). The
essels’ diameters in vivo were estimated in transversal and
ongitudinal axes. The technique is based on a “point-to-
oint” reconstruction of the vessels’ inner circumference.
he presence of thrombosis, stenosis, dilation, or anasto-
otic pseudoaneurysm formation was also checked. The
ative carotids were used as control.
Figure 1 Evolution of PEM During the Entire Experimental Perio
(A) Hematoxylin and eosin/safran histological investigation of (poly(allylamine hyd
implantation (magnification 25). Arrows show the presence of nuclei in arterial w
section treated with PEMrho before implantation (B), at 1 week after (C), and at 1
 75 m). Blue asterisks indicate the lumen localization. PEM  polyelectrolyte mcanning electron microscopy (SEM) examination. The
rafts were collected and washed twice with physiological
erum. They were fixed and prepared as previously described
26). The vessels were observed on an Autoscan S240
ambridge scanning electron microscope (Cambridge,
nited Kingdom) at 80 kV.
istological and immunohistochemistry examination of
rafts. Explanted grafts were dipped in 10% buffered for-
alin and embedded in paraffin. Transverse sections were
ut at 4 different levels, mounted on glass slides, and
ubsequently stained with hematoxylin and eosin/safran
H&S) and van Gieson. Mineralization of the treated
rteries after 12 weeks of implantation was estimated by the
se of the von Kossa reaction according to the methods of
anji et al. (27). The H&S-, van Gieson-, and von
ossa-stained areas were viewed by light microscopy
Olympus IX 50, Center Valley, Pennsylvania). Immuno-
istochemical studies were performed on deparaffinized
ections after epitope restoration, with antibodies directed
gainst -smooth muscle actin (SMA) (1:200, Dako,
ide)/poly(styrene sulfonate))3-treated arteries and untreated arteries before
bservation with confocal laser scanning microscopy of the transversal artery
ks (D) after implantation (magnification 40, numerical aperture 0.8, scale bars
yer film.d
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PEM-Treated Artery: A Patent Vascular Graft November 4, 2008:1589–97lostrup, Denmark) by the use of the streptavidin/biotin
mmunoperoxidase method.
onfocal microscopy. Samples were incubated at 37°C for
0 min with 500 l of monoclonal anti–PECAM-1 (1:50,
ako) in RPMI1640 containing 0.5% bovine serum albu-
in (RPMI1640/BSA). Subsequently, the artery segments
ere washed twice with 1 ml of RPMI1640/BSA to remove
he excess of antibodies. These arteries were incubated for
Figure 2 Blood Velocity Profile and 2-Dimensional Echo-Dopple
(A) Native rabbit carotid, (B) untreated artery, and (C) polyelectrolyte
multilayer film-treated human umbilical artery after 10 weeks of implantation. See
lood Velocity and Vessel Diameter Values for the Nativend PEM-Treated UnA After 2, 4, 7, and 10 Weeks of Implantation
Table 1 Blood Velocity and Vessel Diameter Values for the Natand PEM-Treated UnA After 2, 4, 7, and 10 Weeks of
2 Weeks 4 Weeks
Substitute Native Carotid Substitute Nat
Blood flow, cm/s 43 11 49 9 42 15 5
Diameter, cm 0.27 0.05 0.25 0.02 0.26 0.08 0.2
 6; values are expressed as mean  SD.
PEM  polyelectrolyte multilayer film; UnA  untreated artery.0 min at 37°C with 500 l of polyclonal goat anti-mouse
onjugated with Alexa 488 (1:100, Invitrogen, Carlsbad,
alifornia). After 3 washes in RPMI1640/BSA, the arteries
ere fixed by incubation with 1% paraformaldehyde at 37°C
or 20 min followed by 2 washes with RPMI1640/BSA.
he transversal sections of arteries were visualized by
onfocal laser scanning microscopy (CLSM, SP2-AOBS,
eica, Heidelberg, Germany).
t Examination
Videos 1 and 2.
ntation
7 Weeks 10 Weeks
rotid Substitute Native Carotid Substitute Native Carotid
0 49 11 56 7 59 16 65 10
.03 0.29 0.07 0.25 0.04 0.32 0.06 0.27 0.02r Graf
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November 4, 2008:1589–97 PEM-Treated Artery: A Patent Vascular Graftesults and Discussion
he choice of rabbit as animal model, the bypass procedure,
he extensive arterial injury (arteriotomy and anastomosis),
nd the use of a single heparin dose during surgical
rocedure (lifespan approximately 90 min) (28) constitute
arameters that strongly increase thrombogenic risks. How-
ver, the carotid bypass is a simple process that allowed us to
void surgical complications and trauma compared with
ther implantation sites such as the aorta. Furthermore, the
se of nonimmunosuppressive rabbits, which increase the
Arteries explanted after 12 weeks of 
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PEM treated arteries
Figure 3 SEM Images of Explanted Grafts at 1 and 12 Weeks A
Untreated artery (UnA) (A and B), with polyelectrode multilayer film (PEM)-treated (
artery [HUA]: B) occluded and with pervasive thrombus (A2 and B2) after 1 week o
12 weeks (C2 to F2). After 1 week, the internal surface of the treated arteries (C2
artery surfaces (E2 and F2) showed a similar morphology to the native carotid inte
(A , B , C , D , E , F , G ). SEM  scanning electron microscopy.2 2 2 2 2 2 2isk of graft rejection, represented another challenge for
enograft evaluations. All together, we thus designed con-
itions that increased the failure probability but that were
loser to real surgical situations.
The cryopreserved HUA were de-endothelialized, and
PAH/PSS)3 films were deposited into their lumen surface
nd implanted in rabbit carotids (bypass) for time periods of
week to 3 months. The UnA constituted the negative
ontrol, whereas PEM-treated rabbit carotids allowed us to
ompare the behavior of a modified a xenograft and an
llograft.
PEM treated arteries
eek of implantation
C C2
D D2
Native carotid = control 
G G2
Implantation
) explanted arteries and fresh carotids (G). UnA (Carotid: A; human umbilical
antation. PEM-treated arteries (Carotid: C and E; HUA: D and F) were patent until
2) showed no adherent cells and platelets. After 12 weeks, the treated internal
rface (G2). Original magnification 400 (A, B, C, D, E, F, G) and 1,000r 1 w
fter
C to F
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PEM-Treated Artery: A Patent Vascular Graft November 4, 2008:1589–97The initial regular (PAH/PSS)3 surface coating of the
rteries was checked by 2 complementary approaches. First,
he histological H&S staining showed a specific PEM
oloration (red) (Fig. 1A) compared with UnA (Fig. 1A,
nsert). Moreover, we observed the presence of nuclei in the
ascular wall corresponding to vascular cells (black arrows in
ig. 1A). Second, the use of a rhodamine-labeled PAH
ayer as the third layer with a (PAH/PSS)2-PAH
rho-PSS
urface coating showed a uniform PEM deposit and coverage
f the internal surface (Fig. 1B) once observed by CLSM.
After the surgical procedure, the pulsatile carotid blood
ow re-establishment was visually observed after clamping
emoval. All animals (n  18) survived during the subse-
uent post-operative investigation period (until 3 months).
o apparent neurological, hemorrhagic, or infectious com-
lications were observed in any of the animals during the
xplored experimental time. The in vivo graft patency was
valuated with a noninvasive technique consisting of an
cho Doppler examination performed regularly, every 2
eeks between weeks 2 and 10 (Table 1, Fig. 2). For
EM-treated arteries, the blood flow measurement revealed
ood blood vessel permeability during the entire period of
Figure 4 Histological Examinations of Explanted Grafts at 1 an
UnA (Carotid: A, HUA: B), with PEM-treated arteries after 1 week (Carotid: C, HUA: D)
titia after 1 week. Black arrows indicate the absence of vascular cell, and blue arrow
weeks performed in the explanted arteries treated with PEM indicate the absence of wnvestigations without evidence of aneurysm formation
Online Video 1). For UnA, no Doppler signal was detected
fter only 2 weeks of implantation (Online Video 2),
eflecting a failure blood circulation.
We explanted the grafts after 1, 4, 7, and 12 weeks of
mplantation and submitted them to macroscopic, SEM,
LSM, and histological examinations. We will mainly
ocus on the most important data from the artery harvest-
ngs performed at 1 and 12 weeks. For all implantation
imes, no tissue disintegration and graft rupture at the
nastomosis sites were observed, which constitutes a signa-
ure of excellent graft behavior and an absence of size
ismatch between graft and native carotid (4).
Previous observations were confirmed by SEM examina-
ions of explanted grafts, which showed an occluded lumen
or UnA (Figs. 3A and 3B), with an internal wall clearly
howing a pervasive thrombus for UnA (Figs. 3A2 and 3B2).
he thrombus formation also was confirmed after exami-
ation of the histological sections of arteries stained by
&S (Figs. 4A and 4B).
The PEM-treated arteries showed that all grafts (xeno/
llografts) were patent after 1 week (Figs. 3C and 3D) and
Weeks After Implantation
eeks (Carotid: E, HUA: F). Dotted arrows indicate inflammatory reactions at adven-
ate red PEM after 1 week of implantation. The von Kossa reaction (G and H) at 12
cification. Magnification 40. Abbreviations as in Figures 1 and 3.d 12
or 12 w
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November 4, 2008:1589–97 PEM-Treated Artery: A Patent Vascular Graftp to 12 weeks of implantation (Figs. 3E and 3F). The
EM internal surface observations for the PEM-treated
ascular wall did not show any adhering blood cells after 1
eek (Figs. 3C2 and 3D2) with a fully comparable aspect
escribed before surgery (26). After 12 weeks of implanta-
ion, the lumen of PEM-treated arteries appeared covered
y cells (Figs. 3E2 and 3F2). Compared with fresh carotid
Fig. 3G2), the SEM morphological examination of PEM
reated arteries showed an alike surface aspect. This could be
result of endothelial cell (EC) colonization (see the
ollowing text).
The explanted treated arteries were also subjected to
&S and von Kossa histological examinations. The images
lso demonstrated a perfect blood permeability of luminal
urface arteries treated by PEM for all explored time periods
Figs. 4C to 4E). After 1 week of implantation, the wall
tructure examinations showed (Figs. 4C and 4D): 1) the
resence of the expected chronic inflammatory cells in
rterial adventitia (Figs. 4C and 4D, dotted arrows) prob-
bly due to the healing process (29); 2) the disappearance of
he cells from the media (Figs. 4C and 4D, black arrows)
ue to the absence of vasa vasorum, leading to apoptosis or
ecrosis of cells (30,31); and 3) the presence of PEM and its
egular coating on the internal surface, visualized by H&S
Figure 5 Vascular Wall Remodeling, Cell Identification, and PE
(A) H&S histological examination of PEM-treated arteries. (B) Observations with c
rial wall surface. (C) van Gieson staining showed the presence of elastin fibers in
strated the presence of -SMA cells on the arterial wall (magnification 20). (E)
surface (magnification 40, NA 0.8, scale bars  75 m). H&S  hematoxylin an
cell adhesion molecule; PEM  polyelectrolyte multilayer film; PSS  poly(styreneFigs. 4C and 4D, blue arrows) and confirmed by CLSM
bservations (Fig. 1C), was fully comparable with the
bservations made before implantation (Fig. 1A).
After 12 weeks, the histological analysis of treated arteries
howed (Figs. 4E and 4F): 1) the total absence of the
nflammatory reaction on adventitia; 2) the presence of cells
n the media wall; and moreover; and 3) an absence of wall
rteries biomineralization, which is the signature for the
bsence of an acute graft rejection and failure strengthened
y a negative von Kossa reaction (Figs. 4G and 4H) (27).
ll of these observations seem to confirm a healing process.
The red PEM staining was not further observed on
istological arteries section after 12 weeks of implantation
Figs. 4E, 4F, and 5A). The harvested PEMrho arteries after
2 weeks of implantation were observed by the use of
LSM and showed the presence of rhodamine aggregates
nside the arterial wall (Figs. 1D and 5B). These observa-
ions indicate a strong PEM disturbance probably due to
ascular wall remodeling. This disturbance could eventually
lso indicate growth of new tissue between the film layers
hemselves but more probably the diffusion of fragmented
lm parts within the wall. On the one hand, it is effectively
nown that PAH/PSS layers are stiff materials, favoring cell
dhesion and growth, but on the other hand, the brittleness
ualization After 12 Weeks of Implantation
l laser scanning microscopy (CLSM) showed the presence of PAHrho on the arte-
(purple) and collagen in adventitia (blue). (D) Immunohistochemistry demon-
LSM observations showed the presence of PECAM-1 cells on internal arteries
in/safran; PAH  poly(allylamine hydrochloride); PECAM  platelet endothelial
ate); SMA  smooth muscle actin.M Vis
onfoca
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PEM-Treated Artery: A Patent Vascular Graft November 4, 2008:1589–97f such films could favor the diffusion of complexed poly-
lectrolyte aggregates within the cell wall (32–34).
A last origin of failure of vascular grafts concerns the
eointimal hyperplasia and in anastomosis sites, partly
riginating from an excess of smooth muscle cell (SMC)
roliferation and high extracellular matrix synthesis. The
resent data showed a complete media regeneration. More-
ver, the van Gieson staining showed vascular extracellular
atrix organization with media elastin and adventitia col-
agen localization (Fig. 5C), with a minimal intimal hyper-
lasia at the anastomosis site. The media cell identification,
hrough -SMA expression, demonstrated that cells present
n the arterial wall were -SMA (Fig. 5D), which is a
pecific marker of a SMC phenotype. The mechanism
nvolved in the regeneration of the media vascular grafts
emains unanswered. It is generally observed that the SMC
ecolonization constitutes the ultimate step of a series of
omplex interactions of both cellular and enzymatic systems,
hich are influenced by multiple factors (35–37). Further-
ore, the vessel occlusions at the anastomosis sites due to
he high SMC proliferation were described previously
38–40). Two main reasons were advanced: 1) a compliance
ismatch between vascular grafts and arteries recipient; and
) a lack of EC. Moreover, the histological analysis at the
nastomosis sites showed a minimal SMC proliferation at
he distal anastomosis site.
The internal surface examinations (Figs. 3E, 4F, and 5D)
ndicated the presence of -SMA cells. The identification
f the cell type present on the intimal layer was visualized
ith the use of PECAM-1 expression on CLSM. These
bservations showed luminal surface of treated arteries
overed with PECAM-1 cells, a signature for endothelium
egeneration (Fig. 5E). The supplementary investigations,
erformed after 4 and 7 weeks, demonstrated the presence
f EC only in the neighborhood of anastomosis sites,
uggesting strongly the interstitial invasion of EC from the
ut edge of the adjacent artery.
The re-endothelialization and interstitial invasion may
epend on the regeneration capacity of the individual
ecipient and therefore be dependent on age and health
tatus (41). The regenerative abilities of elderly animals
eem to be lower than for juvenile ones in the sheep model
42). This parameter could in particular influence the
igrative and proliferative function of cells and their capac-
ty for matrix recellularization. In this respect, the use of
uvenile rabbits could represent a certain limitation. Also,
ong-term studies are necessary to validate the benefits of
he presented method as compared to other alternative
pproaches.
onclusions
o our knowledge, this study represents the first report
valuating, in vivo, 1) the potential development of HUA as
ascular grafts; and 2) the thrombogenicity of PEM-treated
rteries. The use of HUA banks represents a bioavailable
1ource with adapted size and with excellent handling char-
cteristics for the surgeons. Our results demonstrate the
ood behavior (no sign of tissue rupture and rejection) and
issue integration of HUA.
The PAH/PSS multilayer film deposit in the luminal
urface avoids the early thrombus formation because this
oating approach limits the accessibility of wall collagen
which is highly thrombogenic) to thrombus factors. Vas-
ular wall regeneration with the recolonization of SMC and
C grafts were obtained after 3 months of implantation.
uch small animal models (i.e., rabbit) are inexpensive and
rovide a good initial in vivo environment to examine
otential therapies. However, to determine whether a ther-
py will be effective in patients, it should be evaluated in a
arge animal model before clinical trials are initiated.
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APPENDIX
or accompanying videos and legends,
lease see the online version of this article.
